Drug Trial Radar · NCT04041310
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Oct 21, 2019
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Nouscom SRLIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ref: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.
Conditions
- Solid Tumor, Adult
Interventions
GAd-209-FSP low doseBiological
GAd20-209-FSP IP, low dose
MVA-209-FSP low doseBiological
MVA-209-FSP IP, low dose
GAd-209-FSP high doseBiological
GAd20-209-FSP IP, high dose
MVA-209-FSP high doseBiological
MVA-209-FSP IP, high dose
GAd20-209-FSP, RP2DBiological
GAd20-209-FSP IP, RP2D
MVA-209-FSP, RP2DBiological
MVA-209-FSP IP, RP2D
KEYTRUDA®Drug
anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicity (DLT assessment), in Phase I, Cohort ATime frame: Within 28 days
- Safety and Tolerability, in Phase I, Cohort A and B.Time frame: Up to 110 weeks
- Overall Response Rate (ORR) at any time during the study, in Phase II (Cohort C and D).Time frame: 18 months
Locations
46 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
City of Hope Comprehensive Cancer Center
Irvine, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
USC Norris Comprehensive Cancer Center
Newport Beach, California
Mt. Sinai
Miami Beach, Florida
Boca Raton Clinical Research
Plantation, Florida
Goshen Center for Cancer Care
Goshen, Indiana
Johns Hopkins University
Baltimore, Maryland
Washington University School of Medicine, Division of Oncology
St Louis, Missouri
Roswell Park Comprehensive Cancer Center
Buffalo, New York
NYU Langone Medical Center
New York, New York
Weill Cornell Medicine / New York-Presbyterian Hospital
New York, New York
MD Anderson Cancer Center (MDACC)
Houston, Texas
Cliniques Universitaires Saint-Luc - Centre du Cancer
Brussels, Belgium
Centre Hospitalier de l'Ardenne - Libramont - Clinique du Sein
Libramont, Belgium
CHU de Liège
Liège, Belgium
Mount Sinai Hospital
Toronto, Canada
Princess Margaret Cancer Center
Toronto, Canada
Aorn Sg Moscati
Avellino, Italy
Candiolo cancer Center,FPO IRCCS
Candiolo, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Ospedale Niguarda
Milan, Italy
AOUS Policlinico Le Scotte
Siena, Italy
Hospital Universitario de A Coruna
A Coruña, Spain
Hospital Del Mar
Barcelona, Spain
Hospital Universitari Dexeus
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia Hospitalet
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Clinica Universidad de Navarra
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Complejo Asistencial de Salamanca
Salamanca, Spain
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.